The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Open Access
- 30 August 2024
- journal article
- research article
- Published by Elsevier in Molecular Metabolism
- Vol. 89, 1-15
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk AS
- CIHR
This publication has 44 references indexed in Scilit:
- Down‐regulated expression of microRNA‐338‐5p contributes to neuropathology in Alzheimer's diseaseThe FASEB Journal, 2018
- DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's diseaseEuropean Journal of Pharmacology, 2018
- APP mouse models for Alzheimer's disease preclinical studiesThe EMBO Journal, 2017
- TREM2/DAP12 Signal Elicits Proinflammatory Response in Microglia and Exacerbates Neuropathic PainThe Journal of Neuroscience, 2016
- Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in MiceDiabetes, 2009
- Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque FormationThe Journal of Neuroscience, 2006
- Morris water maze: procedures for assessing spatial and related forms of learning and memoryNature Protocols, 2006
- Glucagon-like peptide-1 receptor is involved in learning and neuroprotectionNature Medicine, 2003
- Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenesBrain Research, 2001
- Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous systemJournal of Comparative Neurology, 1998